Janssen reports negative results from PHOENIX trial

Janssen Pharmaceutical Companies of Johnson & Johnson has reported negative results from the Phoenix trial after the study failed to meet its primary endpoint.

Free Case Study

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges

By Suvoda

By clicking the Download Free Case Study button, you accept the terms and conditions and acknowledge that your data will be used as described in the Suvoda privacy policy

By downloading this Case Study, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

PHOENIX is a Phase lll, randomised, double-blind, placebo-controlled, multicentre trial designed to analyse the investigational use of Imbruvica (ibrutinib) for the treatment of newly diagnosed non-Germinal Center B cell (non-GCB) subtype of diffuse large B-cell lymphoma (DLBCL).

The trial also compared Imbruvica with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) against R-CHOP, the existing standard of care in DLBCL.

Its primary endpoint included event-free survival in patients with a non-GCB subtype of DLBCL, including an activated B-cell-like (ABC) subtype of DLBCL.

DLBCL is an aggressive form of non-Hodgkin lymphoma (NHL) that affects a type of white blood cell called B-cell lymphocytes.

“We look forward to these regulatory discussions and to submitting the PHOENIX data for presentation at a major medical conference later this year.”

Janssen Research and Development Clinical Development and Global Medical Affairs vice-president Craig Tendler said: “While we are disappointed that the overall study did not result in the outcome that we had hoped for in patients living with DLBCL, we are conducting additional analyses to further understand potential benefits we have observed in a sub-population of patients.

“These analyses will be informative in preparation for upcoming consultations with health authorities.

“We look forward to these regulatory discussions and to submitting the PHOENIX data for presentation at a major medical conference later this year.”

Janssen Biotech , along with Pharmacyclics , has developed Imbruvica, an inhibitor of Bruton’s tyrosine kinase (BTK) protein, which transmits signals that cause B-cells to mature and produce antibodies and is needed by specific cancer cells to multiply and spread.